CARLSBAD, Calif.--(BUSINESS WIRE)--Applied Biosystems, part of Life Technologies Corporation (NASDAQ:LIFE) today announced the commercial availability of the SOLiD™ 3 Plus System, an enhanced next-generation genomic analysis platform designed to allow researchers to move one step closer to performing mainstream sequencing of personal genomes for clinical research and personalized medicine. The technical enhancements to SOLiD 3 Plus include higher throughput, decreased run costs, and faster data analysis which deliver on a roadmap that enables scientists to sequence entire genomes in a more cost-effective and easy manner.
